Medical experts watch the two sessions!

Polypeptide drugs combine the advantages of small molecule drugs and macromolecular protein drugs, and are suitable for the treatment of some complex diseases that are difficult to cure by small molecule drugs.
Polypeptide drugs have high biological activity, strong specificity, and resistance to resistance, etc.
It has become one of the most promising drugs currently
.

At the same time, the average research and development speed of peptide drugs is faster than other innovative chemical drugs and has high druggability; in terms of amino acid composition, with the maturity of peptide synthesis technology, it is currently possible to synthesize more than 50 amino acid molecules; more and more Polypeptide targets have been applied and developed.
With the deepening of basic research, more and more peptide drug targets or receptors will be discovered
.

In recent years, some multinational companies have performed strongly in the peptide drug market by relying on innovative drug molecules and mechanisms of action, and have maintained a double-digit growth rate
.
This shows that in the future, only companies that develop innovative preparations and drug delivery methods can have a place in this field
.

Compared with foreign countries, the market scale of peptide drugs in China is relatively small, but the growth rate is higher than that of the world
.
According to statistics, the scale of China's peptide drug market exceeded 80 billion yuan in 2019, with a compound annual growth rate of over 15%
.
There are about 50 peptide drugs on the market in China, of which imported products occupy the main market
.
Therefore, the domestic peptide industry has huge room for development
.

It is recommended that the development of innovative peptide drugs industry be included in the special development strategy of the 14th Five-Year Plan, which will have a significant impact on the development of innovative peptide drugs in China.
It will speed up the development of innovative peptide drugs and promote the development of peptides by national enterprises.
This is a step for China's new peptide drugs to go global.
A key step to open
.

  Li Wei, Vice President of Guangzhou Bostao Controlled Release Pharmaceuticals:

The way out for generic drugs to stay away from "Red Sea Fighting": high-end preparations

In recent years, under the rules of centralized procurement and consistency evaluation among pharmaceutical companies, the competition of ordinary preparations is very fierce.
For many companies, they often fall into the "red sea fight" of homogenization and low-end
.

In this context, the development of high-end innovative preparations may be one of the outlets for many domestic pharmaceutical companies
.
Compared with the development of new molecular entities, the innovative path of the development of high-end innovative preparations has the advantages of short cycle, less investment and low risk, but the return is not inferior to that of new molecular entities
.

Companies can use new drug delivery systems and other new formulation technologies to develop improved new drugs and improve the safety, effectiveness, and compliance of drugs already on the market
.

For the high-end preparation industry, I suggest that the key links of API companies, excipient companies, pharmaceutical machinery companies, and drug R&D companies should be leveraged to form a synergy
.

At the same time, pharmaceutical companies should do a good job of product quality, improve their own GMP compliance, be familiar with the registration regulations of various countries, and consider issues such as foreign market promotion
.

  Director of American Medical Asia Pacific Marketing-Li Cha:

Pharmaceutical company marketing needs to return to value marketing

Someone once predicted that the rebate-based sales model with gold will end within 3 to 6 years under the consistency evaluation + quantity purchase
.
There is a saying that I know who is swimming naked when the tide goes out
.

Under the continuous promotion of the recruitment policy, the past noise in the industry marketing model has gradually disappeared, and the era of truly testing the company's hardcore strength has arrived
.

It is recommended that medical device marketers stick to the core position of the patient value of the product, return to true value marketing, and tap the "difference" in the "consistency" to withstand the impact of the times
.

At present, the field of biomedicine has become a national key development industry.
How can medical improvement enter the "deep water zone" and "no man's land" to sum up the experience, hold the "null nose" of medical reform, and coordinate the key links of upstream and downstream to form a joint force.
What medical professionals need to work hard for during the 14th Five-Year Plan period
.